Cerebrolysin

Cerebrolysin is a multimodal neuropeptide drug that enhances the brain's ability to heal itself by stimulating the recovery of the nervous system.

Cerebrolysin is used to treat ischemic and hemorrhagic stroke, traumatic brain injury (TBI), various forms of dementia (vascular dementia, Alzheimer's disease) and cognitive disorders, as well as to prevent cognitive decline after brain injury.

treatment DISEASE
Dementia is the loss of cognitive performance to such an extent that it interferes with a person

Dosage form Cerebrolysin:

Solution for injection, amber, transparent.

Composition Cerebrolysin:

1 ml a complex of peptides derived from pig brain 215.2 mg
Excipients: sodium hydroxide, water d / i.

General description Cerebrolysin:

Nootropic drug

Special conditions Cerebrolysin:

If the injections are performed too quickly, a feeling of heat, sweating, and dizziness may occur. Therefore, the drug should be administered slowly.
The compatibility of the drug (within 24 hours at room temperature and in the presence of illumination) with the following standard solutions for infusion was tested and confirmed: 0.9% sodium chloride solution, Ringer's solution, 5% dextrose (glucose) solution.
Simultaneous use of Cerebrolysin with vitamins and drugs that improve cardiac circulation is allowed, however, these drugs should not be mixed in the same syringe with Cerebrolysin.
Cerebrolysin and balanced amino acid solutions should not be mixed in the same solution for infusion.
Only clear solution should be used

Cerebrolysin and only once.
Influence on the ability to drive vehicles and use mechanisms
Clinical trials have shown that Cerebrolysin does not affect the ability to drive vehicles and use mechanisms.
Drug interactions

With the simultaneous use of Cerebrolysin with antidepressants or MAO inhibitors, their action may be mutually reinforced. In such cases, it is recommended to reduce the dose of the antidepressant.
Pharmaceutical interactions
Cerebrolysin is incompatible with solutions that contain lipids and with solutions that change the pH of the medium (5.0-8.0).

Pharmacodynamics Cerebrolysin:

Nootropic drug.
Cerebrolysin contains low molecular weight biologically active neuropeptides that penetrate the BBB and directly enter the nerve cells. The drug has an organ-specific multimodal effect on the brain, i.e. provides metabolic regulation, neuroprotection, functional neuromodulation and neurotrophic activity.
Metabolic regulation: the drug Cerebrolysin increases the efficiency of aerobic energy metabolism in the brain, improves intracellular protein synthesis in the developing and aging brain.
Neuroprotective effect: the drug protects neurons from the damaging effect of lactic acidosis, prevents the formation of free radicals, increases the survival rate and prevents neuronal death under conditions of hypoxia and ischemia, reduces the damaging neurotoxic effect of excitatory amino acids (glutamate).
Neurotrophic activity: Cerebrolysin is the only nootropic peptidergic drug with proven neurotrophic activity, similar to the action of natural neuronal growth factors (NGF), but manifested under conditions of peripheral administration.
Functional neuromodulation: the drug has a positive effect on impaired cognitive functions, improves concentration, memory processes.

Pharmokinetics Cerebrolysin:

The complex composition of Cerebrolysin, the active fraction of which consists of a balanced and stable mixture of biologically active oligopeptides with a total polyfunctional effect, does not allow for the usual pharmacokinetic analysis of individual components.

Indications Cerebrolysin:

- Alzheimer's disease;
- dementia syndrome of various origins;
- chronic cerebrovascular insufficiency;
- ischemic stroke;
- traumatic injuries of the brain and spinal cord;
- mental retardation in children;
- hyperactivity and attention deficit in children;
- endogenous depression resistant to antidepressants (as part of complex therapy).

Contraindications Cerebrolysin:

- acute renal failure;
- status epilepticus;
- hypersensitivity to the drug
Cerebrolysin should be used with caution in the first trimester of pregnancy and during lactation.
The use of the drug during pregnancy and during breastfeeding is possible only if the intended benefit to the mother outweighs the potential risk to the fetus / newborn.
The results of experimental studies do not give grounds to believe that Cerebrolysin has any teratogenic effect or has a toxic effect on the fetus. However, similar clinical studies have not been conducted.

Side effects Cerebrolysin:

Side effects are common (> 1/100, <1/10); rarely (> 1/1000, <1/100); in some cases (> 1/10 000, <1/1000); in isolated cases (<1/10 000).
With excessively rapid administration: rarely - a feeling of heat, sweating, dizziness; in isolated cases - tachycardia or arrhythmia.
From the digestive system: rarely - loss of appetite, dyspepsia, diarrhea, constipation, nausea and vomiting.
From the side of the central nervous system and peripheral nervous system: rarely - excitement, manifested by ar

Application methods Cerebrolysin:

The drug should be administered parenterally. The dose and duration of use depend on the nature and severity of the disease, as well as the age of the patient. A single administration of the drug in a dose of up to 50 ml is possible, however, a course of treatment is more preferable.

The recommended course of treatment is daily injections for 10-20 days.

Indication Dose

Acute conditions (ischemic stroke, traumatic brain injury, complications of neurosurgical operations) from 10 ml to 50 ml

In the residual period of cerebral stroke and traumatic injury to the brain and spinal cord from 5 ml to 50 ml

Psychoorganic syndrome and depression from 5 ml to 30 ml

Alzheimer's disease, dementia of vascular and combined alzheimer-vascular genesis from 5 ml to 30 ml

In neuropediatric practice 0.1-0.2 ml / kg body weight

To increase the effectiveness of treatment, repeated courses can be carried out until the patient's condition improves due to treatment. After the first course, the frequency of injections can be reduced to 2 or 3 times a week.

Cerebrolysin is used parenterally as an intramuscular injection (up to 5 ml) and intravenous injection (up to 10 ml). The drug in a dose of 10 ml to 50 ml is recommended to be administered only by slow intravenous infusions after dilution with standard infusion solutions. The duration of the infusion is 15 to 60 minutes.

After opening the ampoule / vial, the Cerebrolysin solution should be used immediately.